Lactobacillus acidophilus La-14, Lactobacillus rhamnosus HN001, lactoferrin.
Each cap contains: Lactobacillus acidophilus La-14 25 mg; Lactobacillus rhamnosus HN001 11.11 mg; Lactoferrin 50 mg.
Fervacil is an avant-garde oral probiotic which is clinically researched specifically for Bacterial Vaginosis (BV) & Vulvovaginal Candidiasis (VVC).
It combines two strain-specific Lactobacillus strains: L. acidophilus La-14 and L. rhamnosus HN001, together with lactoferrin.
Fervacil helps to normalise vaginal flora balance & provide protection to reduce recurrence of vaginal infections.
ATC Classification: G01AX14-lactobacillus: Belongs to the class of other antiinfectives and antiseptics. Used in the treatment of gynecological infections.
These mechanisms of action have been evaluated through multiple pre-clinical studies: Survive the stomach & reaches the vagina through the gut-to-vagina axis; Adheres strongly to the vaginal epithelium & mucus, competes with pathogens for binding sites & nutrients; Secretes antimicrobial substances that inhibit the growth of pathogens; Dislodge pathogenic biofilm & forms protective biofilm to maintain long-term stability of the vaginal microbiota & reduces recurrence.
Acute & maintenance therapy for BV & VVC.
For acute (15 days): 2 capsules for first 5 days, followed by 1 capsule for next 10 days.
For maintenance (6 months): Take 1 capsule for first 10 days of menstrual cycle.
There is no experience with clinically significant overdosage. However, in case of accidental overdosage, symptomatic treatment should be employed under guidance of a physician.
Hypersensitivity to the active substances or to any of the excipients.
No known special precautions.
Insufficient information currently.
No known adverse reaction/side effects.
No known interaction with other drugs.
Store below 30°C away from sunlight & moisture.
G01AX14 - lactobacillus ; Belongs to the class of other antiinfectives and antiseptics. Used in the treatment of gynecological infections.